Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.

Abstract: The present invention relates to a cooling module (1) for electrical battery cells, comprising a main body (3) in the form of a composite plate and incorporating at least one circuit (4) for the circulation of a heat transfer fluid, between a base plate (6) made of a rigid material with low thermal conductivity and at least one covering plate (8) made of a material with high thermal conductivity, which is intended to come into surface contact with cells of the battery to be cooled, each assembly [cover plate (8)/duct circuit (4)] forming a temperature-controlled reception site.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: In a cutting insert and a milling tool, where the cutting insert is to be on-edge mounted to the tool, the cutting insert includes a polygonal body of wear resistant material. The body includes a first side surface and a second side surface opposing one another and therebetween a number of end surfaces. The intersection of two end surfaces form a cutting edge at a corner portion. The first side surface is substantially planar and the second side surface connects to raised portions at corner portions. The first side surface is greater than the second side surface.

Abstract: In a cutting insert and a milling tool, where the cutting insert is to be on-edge mounted to the tool, the cutting insert includes a polygonal body of wear resistant material. The body includes a first side surface and a second side surface opposing one another and therebetween a number of end surfaces. The intersection of two end surfaces form a cutting edge at a corner portion. The first side surface is substantially planar and the second side surface connects to raised portions at corner portions. The first side surface is greater than the second side surface.

Abstract: Chelates of the compounds of formula I in which R is a hydrophilic group containing 3 or 4 successive phenyl rings and m is 1 or 2, with metal ions, for use in diagnostic imaging.

Abstract: Poly(amino acid) derivatives, which are chelating agents of paramagnetic metal ions, in which at least 3 of the donor nitrogen atoms carry identical or different substituents, of formulaCH(R.sub.1)--X,in which X represents CO.sub.2 R.sub.a, CONR.sub.b R.sub.c or P(R.sub.d)O.sub.2 H and R.sub.a, R.sub.b and R.sub.c, which are identical or different, represent H or optionally hydroxylated (C.sub.1 -C.sub.8)alkyl, R.sub.d represents OH, (C.sub.1 -C.sub.8)alkyl or (C.sub.1 -C.sub.8)alkoxy and R.sub.1 represents a hydrophilic group with a molecular weight greater than 200 containing at least 3 oxygen atoms, with the proviso that at least 3 of the X groups are optionally salified acid functional groups.

Abstract: The invention concerns gadolinium complexes of formula: ##STR1## in which R represents a group of formula: ##STR2## in which X is Br or I; R.sub.1 is H or optionally hydroxylated alkyl;R.sub.2 is hydroxylated alkyl; oralternatively R.sub.1 is H and R.sub.2 is a group of formula: ##STR3## X being as defined above, and R'.sub.1 and R'.sub.2 being as defined for R.sub.1 and R.sub.2 excepted that they do not represent A, provided that --CO--NR.sub.1 R.sub.2 or --CO--NR'.sub.1 R'.sub.2 comprises at least 2 hydroxyl groups, and M represents H or the cation of an inorganic or organic base.

Abstract: Iodized polymers, comprising a skeleton consisting of a dextrane onto which are grafted groups of the formula (I). Application of the these compounds as contrast products.

Abstract: Biological or synthetic macromolecular polyamine compound. optionally of the dendrimer type, characterized in that it carries at least three radio-opaque iodine-containing derivatives.